[go: up one dir, main page]

CO2024006327A2 - Método para el tratamiento de una enfermedad de esclerodermia - Google Patents

Método para el tratamiento de una enfermedad de esclerodermia

Info

Publication number
CO2024006327A2
CO2024006327A2 CONC2024/0006327A CO2024006327A CO2024006327A2 CO 2024006327 A2 CO2024006327 A2 CO 2024006327A2 CO 2024006327 A CO2024006327 A CO 2024006327A CO 2024006327 A2 CO2024006327 A2 CO 2024006327A2
Authority
CO
Colombia
Prior art keywords
treatment
scleroderma
scleroderma disease
disease
antitransglutaminase
Prior art date
Application number
CONC2024/0006327A
Other languages
English (en)
Inventor
Timothy Scott Johnson
John Atkinson
Jorg Hans Wilhelm Distler
David John Abraham
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CO2024006327A2 publication Critical patent/CO2024006327A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo antitransglutaminasa de tipo 2 (TG2) para su uso en el tratamiento de una enfermedad de esclerodermia, tal como la esclerodermia localizada o sistémica.
CONC2024/0006327A 2021-11-18 2024-05-17 Método para el tratamiento de una enfermedad de esclerodermia CO2024006327A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2116665.7A GB202116665D0 (en) 2021-11-18 2021-11-18 Method for the treatment of a scleroderma disease
PCT/EP2022/082293 WO2023089037A1 (en) 2021-11-18 2022-11-17 Method for the treatment of a scleroderma disease

Publications (1)

Publication Number Publication Date
CO2024006327A2 true CO2024006327A2 (es) 2024-07-18

Family

ID=79163875

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0006327A CO2024006327A2 (es) 2021-11-18 2024-05-17 Método para el tratamiento de una enfermedad de esclerodermia

Country Status (13)

Country Link
US (1) US20250026856A1 (es)
EP (1) EP4433516A1 (es)
JP (1) JP2024540595A (es)
CN (1) CN118317977A (es)
AR (1) AR127713A1 (es)
AU (1) AU2022392415A1 (es)
CA (1) CA3238337A1 (es)
CL (1) CL2024001478A1 (es)
CO (1) CO2024006327A2 (es)
GB (1) GB202116665D0 (es)
MX (1) MX2024006091A (es)
TW (1) TW202334241A (es)
WO (1) WO2023089037A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct

Also Published As

Publication number Publication date
CN118317977A (zh) 2024-07-09
WO2023089037A1 (en) 2023-05-25
MX2024006091A (es) 2024-05-30
EP4433516A1 (en) 2024-09-25
GB202116665D0 (en) 2022-01-05
US20250026856A1 (en) 2025-01-23
AU2022392415A1 (en) 2024-06-27
CA3238337A1 (en) 2023-05-25
CL2024001478A1 (es) 2024-09-06
JP2024540595A (ja) 2024-10-31
AR127713A1 (es) 2024-02-21
TW202334241A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
CO2020009625A2 (es) Inhibidor de fap
MX2021013581A (es) Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
AR112072A1 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
CO2022000481A2 (es) Inhibidores de enzimas
ECSP17059101A (es) Composición ácida a base de leonardita y aminoácidos
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
BR112022004861A2 (pt) Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
DOP2020000045A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CO2020005065A2 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
CL2021000950A1 (es) Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717)
MX2020008125A (es) Composiciones que comprenden berberina.
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
CO2024006327A2 (es) Método para el tratamiento de una enfermedad de esclerodermia
CL2019002661A1 (es) Compuestos antineoplásicos.
BR112022020451A2 (pt) Composição de fragrância
MX392348B (es) Anticuerpo anti cd43 y uso del mismo para tratamiento del cáncer.
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano